Comparative Pharmacology
Head-to-head clinical analysis: BLENOXANE versus JELMYTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLENOXANE versus JELMYTO.
BLENOXANE vs JELMYTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bleomycin acts by binding to DNA and inducing single- and double-strand breaks via free radical formation, requiring metal ions (Fe2+, Cu+) and oxygen. It inhibits DNA, RNA, and protein synthesis, with cell cycle phase specificity (G2 and M phases).
JELMYTO (mitomycin) is a mitomycin-containing gel that induces apoptosis by cross-linking DNA, inhibiting DNA synthesis, and producing reactive oxygen species, with additional local tumoricidal effects via thermal ablation of the mitomycin-containing hydrogel.
Blenoxane is administered as 0.25–0.5 units/kg (10–20 units/m²) intravenously, intramuscularly, or subcutaneously once weekly or twice weekly. Typical adult dose: 15–30 units weekly.
Instill 4 mg (1 vial) into the renal pelvis via ureteral catheter or nephrostomy tube, once weekly for 6 weeks, followed by monthly maintenance for up to 11 months. Administer 2 mL of sterile water for irrigation through the catheter to ensure delivery; clamp for 1 hour.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (biphasic: initial 0.5-1 hr, terminal 2-3 hr); prolonged to ~10-20 hours in severe renal impairment (CrCl <30 mL/min)
Following intravesical administration, systemic absorption is negligible, so terminal half-life is not clinically relevant. Mitomycin given intravenously has a terminal half-life of 23-78 minutes (triphasic); this is not applicable for intravesical JELMYTO.
Renal (60-70% as active drug); remainder primarily hepatic metabolism with biliary excretion of metabolites
JELMYTO (mitomycin) is not absorbed systemically after intravesical administration; urinary excretion is the primary route of elimination of the administered dose. Less than 1% of the dose is absorbed and undergoes hepatic metabolism and biliary/fecal excretion.
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic